Navigation Links
Haemonetics Reports Third Quarter of Fiscal 11
Date:1/31/2011

per common share assuming dilution$0.89$0.72Presented below are additional Constant Currency performance measures.  We measure different components of our business at constant currency.  We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates.  These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of $1.20 per Euro, and 110 Yen to the $1.00.  They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.  Non-GAAP revenuesGAAP revenue$176,789$165,169Foreign currency effects(13,369)(11,157)Non-GAAP revenue - constant currency$163,420$154,012Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring and deal integration costs$22,596$18,626Foreign currency effects(5,541)(4,504)Income tax associated with foreign currency effects1,5901,256Non-GAAP net income - constant currency18,64515,378Non-GAAP net income per common share assuming dilutionNon-GAAP net income per common share assuming dilution, adjusted for restructuring and deal integration costs$0.89$0.72Foreign currency effects after tax per common share assuming dilution($0.16)($0.13)Non-GAAP net income per common share assuming dilution - constant currency$0.73$0.59Reconciliation of Non-GAAP Measures for the First Nine Months of FY11 and FY1001/01/1112/26/09Non-GAAP gross profitGAAP gross profit$267,708$249,357Restructuring costs--Non-GAAP gross profit$267,708$249,357Non-GAAP S,G&AGAAP S,G&A$164,078$150,459Restructuring, deal integration and closing costs(6,598)(450)Non-GAAP S,G&A$157,480$150,009Non-GAAP operating expensesGAAP operating expenses$186,054$170,173Restructuring, deal integration and closing costs(6,598)(450)Contingent consideration income1,894-Non-GAAP operating expenses$181,350$169,723Non-GAAP operating income GAAP
'/>"/>
SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
2. Neogen Reports 33% Increase in Net Income
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. New Topical Patent Research Reports Recently Published at MarketPublishers.com
5. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
6. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
7. GeneLink Reports Third Quarter Results
8. Imagenetix, Inc. Reports Second Quarter 2011 Results
9. Transgenomic Reports Third Quarter Financial Results
10. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Protocol Networks brings independent technology ... of brand-neutral, independent consultants, Protocol Networks has recently announced ... over the years, his company has attracted several clients ... Plainfield, as well as others. With the success of ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... 2011 Vermillion, Inc. (NASDAQ: VRML ), a ... call to give a company update following issuance of the ... Conference Call Information To access ... United States and Canada or +1 303 223-2683 internationally.  The ...
... Calif., April 19, 2011 Life Technologies ... will present at Baird,s 2011 Growth Stock Conference on ... Technologies, Chairman and Chief Executive Officer, will present on ... presentation, which will be available for three weeks following ...
... Today, H. Shep Wild, President and Chief Executive ... company focused on the research and development of ... a company overview to venture capital, pharmaceutical and ... Showcase 2011 hosted by the University of Florida ...
Cached Biology Technology:Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 2Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 3Life Technologies to Present at Baird's 2011 Growth Stock Conference 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 3CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics and ... upgradation of the driver,s license is one of the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... Science and the Proceedings of the National ... H. Huang and his colleagues describe the first RNA repair ... second RNA repair system discovered to date (with two proteins ... first). The novelty of the newly discovered bacterial RNA ...
... technology from the developed to the developing world to ... Howard Atkinson (University of Leeds) will report on a ... landmark meeting at Rothamsted Research on Tuesday 13th October ... project aims to enable African scientists to develop, evaluate ...
... stem cells develop into heart muscle in a lab, Duke ... toward growing a living "heart patch" to repair heart tissue ... mouse embryonic stem cells, the bioengineers used a novel mold ... up of heart muscle cells, known as cardiomyocytes. The new ...
Cached Biology News:Researchers discover RNA repair system in bacteria 2New strategy for mending broken hearts? 2
... 1.5L PYREX trypsinizing flasks are ... samples into cell suspensions by ... beaded neck accepts cotton plugs. ... agitation. • Height of Baffles ...
... kit for stabilizing 1.5mg of purified RNA ... for the stabilization of aqueous RNA samples ... such as guanidine, phenol/chloroform, silica, oligo dT ... Kits contain all the necessary components for ...
Plasmid expressing the LacZ reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: